Locations:
Search IconSearch

Ophthalmology

22-EYE-3438365 CQD-Fluid volatility in nAMD-Ehlers

Exudative Stability Key to Anti-VEGF Outcome in nAMD

Advanced OCT features may help individualize treatment intervals

22-EYE-3438364 CQD _ OCT-based imaging biomarkers650x450

Unlocking Precision Medicine in RVO: When Anti-VEGF Therapy Isn’t Effective

Intraretinal fluid volumes and other features detectable with OCT may help predict treatment response

23-EYE-3521610 CQD-Time to resolution of DME-Talcott-650×450
February 8, 2023/Diabetes & Endocrinology

Diabetic Macular Edema Can Take 1-2 Years to Resolve in Patients Despite Aggressive Treatment

Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Featured Image for the post
September 22, 2022/Ophthalmology/News & Insight

Unlocking the Potential of OCT: From Imaging to Biomarker Discovery

Innovative work earns ASRS and Macula Society awards for Justis P. Ehlers, MD

Eye drops

Hypertension Drug Losartan Reverses Scarring and Restores Vision After Cornea Damage

Studies indicate dramatic results when used topically with or without corticosteroids

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

22-EYE-2953384-CQD-Case study on pat with ocular migraines-str-Bajic

Case Study: When Ocular Migraine Symptoms Indicate Impending Stroke

Subtle but important distinctions for ophthalmologists

BackPage 6 of 16Next

Advertisement

Ad